Adverum Biotechnologies — Q4 2020 Earnings Presentation
22 slides from Adverum Biotechnologies's earnings presentation, Mar 1, 2021

Slide 1: Preserving Sight for Life
Preserving Sight for Life TM March 1, 2021 Nasdaq: ADVM

Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include,

Slide 3: Opening Remarks
Opening Remarks Laurent Fischer, M.D. Chief Executive Officer 33

Slide 4: Building Momentum
BUILDING MOMENTUM 4

Slide 5: Today's Agenda
Topic Speaker Laurent Fischer, M.D. Opening Remarks and Recent Highlights Chief Executive Officer Pivotal Program for ADVM-022, a Single, In-Office Aaron Osborne, M.B.B.S. IVT Injection Gene Therapy Candidate for Chief Medical Officer Wet AMD Arshad M. Khanani, M.D., M.A. Patient and Investigator Ex

Slide 6: ADVM-022 Path to BLA Submission 2024 in Wet AMD
ADVM-022 Path to BLA Submission 2024 in Wet AMD OPTIC trial demonstrated ADVM-022’s continued robust treatment response, long-term durability, and favorable safety profile in difficult-to-treat wet AMD patients Positive Outcome from • Alignment on clinical development and CMC requirements Recent FDA

Slide 7: Durable Treatment to Reduce Injection Frequency is the Largest Unmet Need
Durable Treatment to Reduce Injection Frequency is the Largest Unmet Need Largest unmet needs for Wet AMD patients as reported by retina specialists (Number of mentions, N=30*) Decrease injection frequency 28 Better efficacy 11 MORE OFTEN NAMED (UNPROMPTED) Easier administration Better control of ma

Slide 8: ADVM-022 Offers Potential for Life-Long Vision Benefit
ADVM-022 Offers Potential for Life-Long Vision Benefit IVT gene therapy may provide one-and-done anti-VEGF treatment Q4W ADVM-022 Route of Administration In-office Q4W-Q8W In-office IVT Injection 2Y+ Q8W-Q12W Faricimab Q8-16W* KSI-301 Q12W - Q20W* Port Delivery System RGX-314 with ranibizumab Surgic

Slide 9: A Single IVT Injection of ADVM-022 has the Potential to Transform the Current Standard of Care in Wet AMD
A Single IVT Injection of ADVM-022 has the Potential to Transform the Current Standard of Care in Wet AMD Efficacy & Durability* Safety* Injection Frequency* Majority of patients in 2x1011 vg/eye cohorts are supplemental anti-VEGF Well tolerated with a favorable safety profile: 85% reduction in annu

Slide 10: ADVM-022 Pivotal Program
ADVM-022 Pivotal Program Aaron Osborne, M.B.B.S. Chief Medical Officer 10

Slide 11: Majority of Patients are Supplemental Injection Free after a Single IVT Injection of ADVM-022
Majority of Patients are Supplemental Injection Free after a Single IVT Injection of ADVM-022 in OPTIC Frequent anti-VEGF injections prior to ADVM-022 6x1011 vg Cohort 1 1* 2 6/6 3 Supplemental 4 Injection-free 5 6 1 2 2x1011 vg Cohort 2 3 3/6 Supplemental Injection-free 4 5 6 1 2 3 2x1011 vg 4 Coho

Slide 12: Reduction in Annualized Anti-VEGF Injections Following ADVM-022
Reduction in Annualized Anti-VEGF Injections Following ADVM-022 Mean Prior Annual Rate Mean Post ADVM-022 Annual Rate Mean Annualized Number of anti-VEGF Injections 11 10.0 10.0 10 9 8 7 6 99% Reduction 85% Reduction 5 4 3 2 1.5 1 0.1 0 High Dose High Dose Low 2E11 vg/eye Dose Dose (Cohorts 2+3) (6×

Slide 13: Well Tolerated with a Favorable Safety Profile at High and Low Doses
Well Tolerated with a Favorable Safety Profile at High and Low Doses Overall Safety Profile Inflammation Resolving with Steroid Eye Drops High Dose Low Dose • ADVM-022-related ocular AEs were mild (78%) to (6×1011 vg/eye) (2×1011 vg/eye) 1+ moderate (22%) Mean Aqueous Cell Grade 0.5+ • No ADVM-022-r

Slide 14: 2x10^11 vg/eye Cohorts 2+3: Improved Vision and Retinal Anatomy
2x1011 vg/eye Cohorts 2+3: Improved Vision and Retinal Anatomy in Supplemental IVT-free Patients Mean (90% CI) by Visit Through Week 32* Outcomes as of 15 October 2020 80 32–68 weeks Follow-Up Mean BCVA, Letters 70 (median 48) 60 Supplemental IVT-Free Patients 67% (10/15) 50 Mean BCVA Change from Ba

Slide 15: ADVM-022 Planned Global Phase 3 Trials in a Broad Wet AMD Population
ADVM-022 Planned Global Phase 3 Trials in a Broad Wet AMD Population Key Objectives Primary Subjects: 900 Patients Across 2 Studies • To evaluate mean change in best corrected visual • ADVM-022 dosed intravitreally (in-office) acuity (BCVA) of ADVM-022 at 1x1011 vg/eye and • Diagnosis of subfoveal C

Slide 16: Advancing Gene Therapies Pipeline
OPTIC Case Study: Advancing Rapid Pipeline and Sustained Gene of Transformative Improvements Therapies to Ocular Anatomy and Vision Preclinical Phase 1 Phase 2 Phase 3 ADVM-022 for Wet AMD OPTIC (n=30) Dose exploration in Enrollment complete 3yr extension difficult-to-treat patients Comparison again

Slide 17: OPTIC Case Study: Long-term Anatomical and Vision Improvements
OPTIC Case Study: Long-term Anatomical and Vision Improvements OPTIC afterCase Study: a Single IVTRapid and of Injection Sustained ADVM-022Improvements to Ocular Anatomy and Vision Prior to ADVM-022 68 weeks after ADVM-022* BCVA 63 letters BCVA 69 letters 10 prior anti-VEGF injections with persisten

Slide 18: OPTIC Case Study: Rapid and Sustained Improvements to Ocular Anatomy and Vision
OPTICCase OPTIC CaseStudy: Study:Rapid Rapidand andSustained SustainedImprovements ImprovementstotoOcular OcularAnatomy Anatomy and Vision and Vision after Single IVT Injection of ADVM-022 Persistent fluid despite frequent anti-VEGF Rapid and sustained anatomical injections improvement after ADVM-02

Slide 19: Fireside Chat
Fireside Chat Laurent Fischer, M.D. Arshad M. Khanani, M.D., M.A. Chief Executive Officer Director of Clinical Research, Sierra Eye Associates; Investigator in OPTIC and INFINITY Trials 19

Slide 20: Fully Integrated Gene Tx Company: ADVM-022 BLA Submission Anticipated in 2024
Fully Integrated Gene Tx Company: ADVM-022 BLA Submission Anticipated in 2024 2021 Present Long-term OPTIC Data Q2 Wet DME & 2021 INFINITY DME Ph2 Data H2 2021 Initiate Pivotal Ph3 Studies Q4 AMD DR 2022 Initiate DME Pivotal Studies 2023 Topline Pivotal Data 2024 BLA Submission 2021 Long-term NHP Da

Slide 21: Our Global Mission
Our Global Mission To establish ocular gene therapy as a one-time treatment that preserves patient sight for life 21

Slide 22: Adverum
RDVERUM
Source: EarningsCall slides
More decks from Adverum Biotechnologies Inc
FLORetina December 202519 slides · Dec 4, 2025
Technical Presentation (November 2024)78 slides · Nov 18, 2024
Corporate Update (July 2024)39 slides · Jul 17, 2024
Technical Presentation (February 2024)32 slides · Feb 8, 2024
Proxy Contest (April 2021)10 slides · Apr 26, 2021
Proxy Contest (April 2021)65 slides · Apr 22, 2021